文献速递核素与放射性配体治疗

中肠神经内分泌肿瘤患者肽受体放射性核素治疗后的生活质量

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-07-24

本研究纳入70例中肠神经内分泌肿瘤患者,分析177Lu-DOTATATE肽受体放射性核素治疗(PRRT)对健康相关生活质量的影响。结果显示,整体健康状况在第1、2、3周期后显著改善,情绪和认知功能亦改善,疼痛和腹泻在第2、3周期后显著减轻。高功能状态与中等功能状态患者的生活质量改善无显著差异。

要点

  • PRRT可显著改善中肠NET患者整体健康状况、情绪功能、认知功能及疼痛腹泻症状。
  • ECOG 0-1与ECOG 2患者的生活质量改善程度无显著差异。

核心结论

  • PRRT对高或中等功能状态的中肠NET患者生活质量均有积极改善作用。

研究设计与样本

  • 纳入70例中肠NET患者(39男31女),平均年龄64.2岁,采用EORTC QLQ-C30问卷在基线和每周期PRRT后3个月评估生活质量。

主要发现

  • 整体健康状况在第1周期(p=0.05)、第2周期(p=0.004)、第3周期(p=0.04)后较基线显著改善。
  • 情绪功能在第1、2周期(均p<0.001)及第3周期(p=0.001)后显著改善,认知功能在第1周期(p=0.003)和第2周期(p=0.05)后显著改善。
  • 疼痛和腹泻在第2周期(p=0.038)和第3周期(p=0.036)后显著减轻。
  • 高功能状态(ECOG 0或1)与中等功能状态患者的生活质量变化无显著差异。

关键数值与推荐

  • 中位累积给药活度为27.4 GBq。

临床怎么用

  • PRRT在改善中肠NET患者生存之外,可同步改善整体健康、情绪认知功能及疼痛腹泻症状,且获益不受基线功能状态限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There is convincing evidence that peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE compared to octreotide therapy has a positive effect on overall survival and progression-free survival in midgut neuroendocrine tumors (NET). The current study analyzed health-related quality of life (QoL) in patients undergoing PRRT with a special focus on differences in functional performance. MATERIALS AND METHODS: In our study, 70 patients (39 men or 31 female) suffering from midgut NET were included, with a mean age of 64.2 years. Functional performance was assessed by the index of the Eastern Cooperative of Oncology Group (ECOG). Thirty-three patients (47%) showed ECOG 0, 31 patients (44%) ECOG 1, and six patients (9%) ECOG 2. Health-related QoL was assessed by the EORTC QLQ-C30 questionnaire filled in at baseline and 3 months after each PRRT cycle. RESULTS: The median cumulative administered activity was 27.4 GBq. Global health status significantly improved compared to baseline status after 1st (p = 0.05), 2nd (p = 0.004), and 3rd (p = 0.04) treatment cycle. Analyzing specific aspects of QoL, emotional functioning significantly improved after 1st and 2nd treatment cycle (both p < 0.001) as well as after 3rd cycle (p = 0.001). With regard to cognitive functioning, there was a significant improvement after 1st and 2nd treatment cycle (p = 0.003 and p = 0.05 respectively). With regard to alleviation of somatic symptoms, a significant reduction in pain and diarrhea was observed after the 2nd cycle (p = 0.038) and 3rd cycle (p = 0.036). Furthermore, changes in QoL in relation to functional performance status as assessed by ECOG were analyzed. There were no significant differences with regard to QoL alterations between patients with high (ECOG 0 or 1) and moderate performance status. CONCLUSION: Our study confirmed an equally positive effect of PRRT on quality of life in midgut NET patients with high or moderate functional status in terms of increasing global health, functional status, and alleviating symptoms.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Marinova M, Mücke M, Fischer F, et al. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2019. PMID: 31338547. doi:10.1007/s00259-019-04431-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。